

Estimating Baseline Kidney Function in Hospitalized Patients with Impaired Kidney Function

Edward D. Siew,* T. Alp Ikizler,* Michael E. Matheny,^{†‡§||¶} Yaping Shi,[¶] Jonathan S. Schildcrout,[¶] Ioana Danciu,[§] Jamie P. Dwyer,* Manakan Srichai,* Adriana M. Hung,^{***} James P. Smith,^{††} and Josh F. Peterson^{†§||}

Summary

Background and objectives Inaccurate determination of baseline kidney function can misclassify acute kidney injury (AKI) and affect the study of AKI-related outcomes. No consensus exists on how to optimally determine baseline kidney function when multiple preadmission creatinine measurements are available.

Design, setting, participants, & measurements The accuracy of commonly used methods for estimating baseline serum creatinine was compared with that of a reference standard adjudicated by a panel of board-certified nephrologists in 379 patients with AKI or CKD admitted to a tertiary referral center.

Results Agreement between estimating methods and the reference standard was highest when using creatinine values measured 7–365 days before admission. During this interval, the intraclass correlation coefficient (ICC) for the mean outpatient serum creatinine level (0.91 [95% confidence interval (CI), 0.88–0.92]) was higher than the most recent outpatient (ICC, 0.84 [95% CI, 0.80–0.88]; $P < 0.001$) and the nadir outpatient (ICC, 0.83 [95% CI, 0.76–0.87]; $P < 0.001$) serum creatinine. Using the final creatinine value from a prior inpatient admission increased the ICC of the most recent outpatient creatinine method (0.88 [95% CI, 0.85–0.91]). Performance of all methods declined or was unchanged when the time interval was broadened to 2 years or included serum creatinine measured within a week of admission.

Conclusions The mean outpatient serum creatinine measured within a year of hospitalization most closely approximates nephrologist-adjudicated serum creatinine values.

Clin J Am Soc Nephrol 7: 712–719, 2012. doi: 10.2215/CJN.10821011

Introduction

Acute kidney injury (AKI) is common among hospitalized patients and is independently associated with morbidity and mortality. Although recently accepted diagnostic criteria rely on relative or fixed changes in serum creatinine, published studies have differed in their approach to determining baseline kidney function (1–9). We have previously demonstrated that the use of inpatient values or a single estimate of baseline kidney function results in bidirectional misclassification of AKI incidence and severity (10). In studies for which preadmission serum creatinine data are available, an optimal approach to identifying baseline kidney function has not been identified.

In this study, we examined preadmission serum creatinine measurements in a cohort of 379 high-risk patients admitted to a tertiary care academic medical center over a 12-month period. The study objective was to examine how commonly used methods for estimating baseline kidney function, including using the most recent, average, or nadir serum creatinine values, most closely approximated clinical nephrology opinion. We measured agreement between each of these commonly applied algorithms to a reference standard for baseline serum creatinine as determined by a blinded panel of

board-certified nephrologists. We also examined how performance of each algorithm varied with the time interval chosen up to 2 years before admission.

Materials and Methods

Study Population

Adult patients (≥ 18 years of age) were eligible if admitted to Vanderbilt University Hospital for ≥ 24 continuous hours between October 1, 2007, and October 1, 2008. As the main adult inpatient facility within Vanderbilt University Medical Center (VUMC), Vanderbilt University Hospital is a large tertiary referral center serving middle Tennessee and surrounding areas. Because patients without preadmission serum creatinine data will require a surrogate baseline value whereas those with only one preadmission value do not require a specific selection algorithm (10, 11), we required study patients to have at least two creatinine values recorded in their electronic medical record within 24 months before hospitalization. Our aim was to focus on patients for whom determination of baseline kidney function might differ on the basis of the selection approach used (*e.g.*, nadir, mean, most recent), thereby influencing AKI classification and staging.

*Department of Medicine, Division of Nephrology, §Department of Biomedical Informatics, ||Department of Medicine, Division of General Internal Medicine and Public Health, and ¶Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee; †Geriatric Research Education Clinical Center, ‡Health Services Research and Development, and **Clinical Science Research and Development, Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee; and ††Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan

Correspondence: Dr. Edward D. Siew, MSCI Vanderbilt University Medical Center, 1161 21st Avenue South S3223, MCN, Nashville, TN 37232. Email: edward.siew@vanderbilt.edu

We selected a population with evidence of impaired renal function on admission (estimated GFR < 60 ml/min per 1.73 m²) or AKI defined by Acute Kidney Injury Network diagnostic criteria (increase in serum creatinine of 0.3 mg/dl or 50% over any 48-hour interval). The study excluded patients with previous evidence of stage 5 CKD or ESRD according to prior International Classification of Diseases, Ninth Revision (ICD-9), code assignment of 585.6, 996.73, 996.68, 996.56, 792.5, or 458.21. For patients with multiple admissions, a single admission was chosen at random for evaluation. The VUMC Institutional Review Board approved the study protocol. Retrospective patient records were anonymized for analysis and the institutional review board approved waiver of consent.

Data Collection

General demographic information and laboratory data were collected from the institutional electronic medical record, which serves inpatients and outpatients at VUMC. Creatinine measurements were retrieved for each eligible patient for 2 years before admission. Information on comorbid conditions was identified using the corresponding ICD-9 codes for diabetes mellitus, hypertension, coronary artery disease, cerebrovascular disease, congestive heart failure, and peripheral vascular disease assigned before hospitalization (Appendix 1).

Adjudication of Baseline Kidney Function

Two board-certified nephrologists (M.S., J.P.D.) served as primary reviewers and were asked to determine a pre-admission creatinine value that best reflected each patient's baseline kidney function immediately before the acute illness that had prompted hospitalization. Reviewers were given access to the entire preadmission electronic medical records, including outpatient notes, problem lists, previous hospitalizations, emergency department or acute clinic visits, radiographic studies, consultations, any and all laboratory values measured at primary institution, and outside creatinine values obtained and scanned into the chart. The overarching goal was to reflect a similar clinical practice environment encountered by nephrologists asked to see a patient shortly after admission. We did not insist that a specific documented pre-existing value be used but rather allowed the adjudicators the flexibility to present a value that they thought best represented each patient's baseline. For example, if a patient had several values of 0.8 mg/dl and 1.0 mg/dl, the adjudicator was allowed to enter 0.9 mg/dl if he or she thought it most representative of the patient's baseline after examining the clinical scenario in which previous measurements were made.

Disagreement between reviewers was classified as a ≥ 0.2 -mg/dl difference in baseline creatinine assessment if the lesser of two values chosen was ≤ 2.0 mg/dl, or as a >10% difference if the lesser of two values chosen was >2.0 mg/dl. The standard for disagreement was selected by considering the following: (1) the analytical coefficient of variation and the intra-individual coefficient of variation that contribute to an overall variation of 10%–20% (11, 12) and (2) the consensus opinion of a panel of local board-certified nephrologists. When the primary reviewers agreed, the final baseline creatinine value was the mean of

the two chosen values. In cases of disagreement, the two primary reviewers and an independent board-certified nephrologist (A.M.H.) reviewed the case. To remain consistent with methods used for the primary reviewers, the final creatinine value was then determined using the mean between the third reviewer and the closer of the two chosen values from the primary reviewers.

Comparison between Baseline Estimation Algorithms and Clinical Nephrologist Opinion

After adjudicated determination of baseline creatinine as a reference standard, we compared the following algorithms for estimating baseline creatinine: (1) the mean outpatient value, (2) the most recent outpatient value, (3) the nadir outpatient value, and (4) the most recent inpatient or outpatient value. Three time intervals were also chosen for study: 7–365, 7–730, and 1–730 days before admission.

Statistical Analyses

Categorical and continuous variables were summarized using percentages and median and interquartile range (IQR), respectively. The intraclass correlation coefficient (ICC) with 95% confidence interval (CI) was used to measure the agreement between reviewers as well as between the final adjudicated serum creatinine values and surrogate estimation methods. Bland-Altman plots were used to illustrate agreement between surrogate estimation methods and the reference standards across the range of serum creatinine values. Pairwise comparisons of ICCs were conducted using the Konishi-Gupta modified Z test (13). Because overlap in creatinine value availability was incomplete between time intervals, only comparisons between estimation methods within the same intervals with identical availability were compared. *P* values from multiple comparisons were adjusted using the Bonferroni method. Analyses were performed using R 2.13.0 (R Foundation for Statistical Computing, Vienna, Austria) and SAS software, version 9.2 (SAS Institute, Inc., Cary, NC). A two-sided *P* value < 0.05 was considered to indicate a statistically significant result.

Results

Among 13,781 adult patients hospitalized with AKI or impaired GFR on admission, 400 were randomly selected for the study population. Twenty-one patients without a valid measurement of serum creatinine during hospitalization or with no serum creatinine value measured before admission were excluded. Table 1 lists the demographic, comorbidity, and hospital characteristics of the study population. A slight female predominance (53%) was observed, and most patients self-identified as white (83%). At index admission, patient comorbid conditions included hypertension (65%), diabetes mellitus (35%), coronary artery disease (43%), and congestive heart failure (32%).

Preadmission Serum Creatinine Availability

Figure 1 depicts the availability and counts of preadmission serum creatinine values grouped by time interval. A median of 8 (IQR, 3–18) total, 3 (IQR, 1–8) outpatient, and 3 (IQR, 0–9) inpatient creatinine measurements were recorded between 1 and 730 days before admission. A substantial portion of total creatinine measurements (median, 5 [IQR, 2–13]) occurred

Table 1. Population demographic and comorbidity characteristics

Baseline Characteristic	Value (n=379)
Median age (yr)	65 (46–75)
Female, n (%)	201 (53)
Ethnicity, n (%)	
white	314 (83)
African-American	54 (14)
other	11 (3)
Diabetes mellitus, n (%)	134 (35)
Hypertension, n (%)	245 (65)
Coronary artery disease, n (%)	163 (43)
Chronic heart failure, n (%)	122 (32)
Cerebrovascular disease, n (%)	95 (25)
Peripheral vascular disease, n (%)	59 (16)
Chronic liver disease, n (%)	42 (11)
Admission service, % (n/n)	
medical	74 (280/379)
surgical	23 (87/379)
other	3 (12/379) ^a
ICU within 7 days of admission, n (%)	126 (33)
Median adjudicated baseline creatinine (mg/dl)	1.35 (1.03–1.70)
Mean adjudicated baseline creatinine ± SD (mg/dl)	1.45 ± 0.61
Median adjudicated baseline eGFR (ml/min per 1.73 m ²)	49 (38–67)
< 60 ml/min per 1.73 m ² , n (%)	68 (259)
30–59.9 ml/min per 1.73 m ² , n (%)	58 (220)
<30 ml/min per 1.73 m ² , n (%)	10 (39)
Median admission serum creatinine (mg/dl)	1.46 (1.09–2.00)
Mean admission serum creatinine ± SD (mg/dl)	1.75 ± 1.19
Acute kidney injury stage, n (%)	
stage I	35 (133)
stage II	34 (9)
stage III	11 (42)
Median values are expressed with interquartile ranges in parentheses. ICU, intensive care unit; eGFR, estimated GFR.	
^a Services providing both surgical and medical care are categorized as “Other.”	

within 7–365 days before admission, with a median time to first serum creatinine of 16 days (IQR, 6–67 days) before admission. Twenty-nine percent of patients had at least one serum creatinine value within a week of admission (range, 1–7 days), and 97.4% of patients had creatinine values between 7 and 730 days before admission.

Comparison of Adjudicated Baseline Serum Creatinine with Prespecified Estimation Methods

Overall agreement between the primary reviewers on baseline serum creatinine values was 88%, with an ICC of 0.93 (95% CI, 0.91–0.94). A third independent reviewer (A.M.H.) resolved 45 (12%) cases of disagreement. Median final adjudicated baseline creatinine and estimated GFR values were 1.4 mg/dl and 49 ml/kg per 1.73 m², respectively.

Table 2 shows the prespecified estimation methods studied, which included the most recent outpatient, the mean outpatient, the nadir outpatient, and the most recent inpatient or outpatient measure taken from the preadmission time intervals. The highest overall ICCs were noted for estimation methods using creatinine values between 7 and 365 days (ICC range, 0.83–0.91) before admission. Among outpatient values, an ICC of 0.91 (95% CI, 0.88–0.92) for the mean outpatient serum creatinine was higher than the ICCs for both the most recent outpatient creatinine (0.84 [95% CI, 0.80–0.88]; $P < 0.001$) and the nadir outpatient serum creatinine (0.83 [95% CI, 0.76–0.87]; $P < 0.001$). Allowance of the final creatinine measurement from a prior inpatient stay during the 7- to 365-day interval increased the ICC of the most recent outpatient value to 0.88 (95% CI, 0.85–0.91).

Extending the prehospitalization time interval increased the proportion of patients with baseline creatinine values available for assessment. In our study cohort, extending the time interval from 7–365 days to either 7–730 days or the entire 2-year interval (1–730 days) increased the proportion of patients with at least one outpatient creatinine value available from 81% ($n=306$) to 85% ($n=321$) or to 87% ($n=329$), respectively. Allowing the final inpatient creatinine to be included when an outpatient value was not available for most recent outpatient visit also increased the proportion of patients available to 93% ($n=355$). However, accuracy decreased as the time interval increased. For example, when the time interval was increased from 7–365 to 7–730 days before admission, the ICC for the mean outpatient value decreased from 0.91 (95% CI, 0.88–0.92) to 0.81 (95% CI, 0.77–0.84). Similarly, the nadir outpatient ICC was reduced from 0.83 (95% CI, 0.76–0.87) to 0.64 (95% CI, 0.46–0.75). Reductions in the most recent outpatient or most recent inpatient or outpatient method were more modest, at 0.84 (95% CI, 0.80–0.88) to 0.83 (95% CI, 0.78–0.86) and 0.88 (95% CI, 0.85–0.91) to 0.88 (95% CI, 0.85–0.91), respectively. Adding creatinine data from the week before (1–7 days) hospital admission resulted in poorer performance using mean outpatient, most recent outpatient, and most recent inpatient or outpatient methods.

Figure 2 illustrates the agreement between estimation methods for the 7- to 365-day time interval and adjudicated creatinine values. In addition, the proportion of estimated values decreasing at least 0.3 mg/dl above or below the adjudicated value is highlighted and drawn as an indicator of potential AKI misclassification. The mean outpatient serum creatinine, the most recent outpatient value, and most recent inpatient or outpatient methods had similar proportions of patients with decreases of at least 0.3 mg/dl above or below the adjudicated value, at 11.1%, 13.7%, and 12.1%, respectively. In most of these cases, estimated baseline creatinine values were higher than the adjudicated value. In contrast, using the nadir outpatient serum creatinine resulted in 20.3% of estimated baseline values decreasing at least 0.3 mg/dl above or below the adjudicated serum creatinine value. In most of these cases, nadir serum creatinine was lower than the adjudicated creatinine value. In all estimation methods, the direction of the overall estimation error remained consistent as the time interval broadened while the proportion of patients falling outside of a 0.3-mg/dl deviation increased (data not shown).




Figure 1. | Preadmission creatinine value availability. Data are shown as box plots grouped by days before admission on the x-axis and further stratified by inpatient, outpatient, or either location of measurement. Counts of measurement are indicated on the y-axis. Horizontal lines within each box denote the median number of available serum creatinine counts, with the bottom and top of each box representing the 25th and 75th percentiles, respectively. The bottom/top whisker corresponds to the lowest/highest count that falls within 1.5 times the interquartile range below/above the 25th/75th percentile of counts.

Estimation Method	ICC (95% CI) per Days Before Admission		
	7–365 d	7–730 d	1–730 d
Most recent outpatient	0.84 (0.80–0.88) ^a	0.83 (0.78–0.86) ^b	0.74 (0.68–0.79) ^c
Mean outpatient	0.91 (0.88–0.92) ^a	0.81 (0.77–0.84) ^b	0.71 (0.65–0.76) ^c
Nadir outpatient	0.83 (0.76–0.87) ^a	0.64 (0.46–0.75) ^b	0.68 (0.31–0.83) ^c
Most recent inpatient or outpatient	0.88 (0.85–0.91) ^d	0.88 (0.85–0.91) ^d	0.80 (0.76–0.84) ^e

All comparisons are made to the reference standard. ICC is calculated using a population of patients with sufficient creatinine values to yield an estimation method result. ICC, intraclass correlation coefficient; CI, confidence interval.

^an=306 patient (81% of cohort).
^bn=321 patients (85% of cohort).
^cn=329 patients (87% of cohort).
^dn=355 patients (93% of cohort).
^en=379 patients (100% of cohort).

Sensitivity Analyses

We performed two companion analyses. Because pre-existing CKD is a major challenge in assessing baseline kidney function, we enriched our study population for those with abnormal kidney function. Table 3 shows the ICCs for each estimation algorithm stratified according to baseline CKD status, defined as an eGFR derived from the adjudicated serum creatinine value of <60 ml/min per 1.73 m² for the 7- to 365-day interval before hospitalization. For

patients with and those without CKD, mean outpatient serum creatinine represented a closer approximation of clinical nephrology opinion than did other algorithms tested.

Because the main study site involved a large academic tertiary referral center, the study population probably comprised patients from various practice settings and comorbidity backgrounds. To account for the effects of potential ascertainment bias of preadmission serum creatinine data,




Figure 2. | Bland-Altman plots comparing selected approaches for estimating baseline kidney function with expert adjudication during the 7- to 365-day time interval. (A) Most recent outpatient. (B) Mean outpatient. (C) Nadir outpatient. (D) Most recent inpatient or outpatient. x-axis represents the average of serum creatinine (SCr) value between the estimation method and adjudicated value. y-axis indicates the difference in serum creatinine values between the adjudicated value and the estimation method. The dotted lines represent a 0.3-mg/dl deviation in either direction. The right side of each figure shows a histogram of the difference between the adjudicated value and the estimation method. The percentage values show the potential bias in AKI diagnosis indicating the estimated values at least 0.3 mg/dl deviations above or below the adjudicated value. ICC, intraclass correlation coefficient.

we further stratified our analysis by the number of creatinine measurements available during the 7- to 365-day preadmission time interval (Table 3). Patients were grouped into tertiles based on preadmission creatinine measurement availability (0–6, 6–14, and 14–93 values). ICCs for the mean outpatient algorithm were consistently higher than those for other algorithms tested within each tertile of creatinine availability.

Discussion

Accurate determination of baseline kidney function anchors the definition of AKI and establishes a longitudinal

reference point in studies examining the long-term consequences of AKI (14). Variability in applied baselines can contribute to heterogeneity in reported AKI frequency (2,9,10,15), reduce fidelity during cross-validation, and confound examination of the longitudinal effect of AKI (14). We have shown that among high-risk patients, use of a mean outpatient serum creatinine between 7 and 365 days before admission most closely approximates clinical nephrology opinion for determining baseline kidney function. Higher ICCs yielded lower rates of potential AKI misclassification at baseline. The results also suggest that broadening the temporal detection window increases the number of patients with sufficient information to




Figure 2. | Continued

establish a baseline at the expense of reduced accuracy in the estimate.

Modern consensus definitions have helped to standardize how AKI is detected and compared across multiple settings (16,17). The Acute Kidney Injury Network definition currently relies on a rolling 48-hour window of detection for AKI (1). This specification helps to decrease the ambiguity in using functional markers for ensuring injury acuity and may be reasonable in patients with well preserved kidney function on presentation. However, the risks of not accounting for preadmission kidney function, particularly among those with abnormal kidney function on presentation, are considerable and include bidirectional misclassification of disease status (10). This potential source of error is amplified further with modest changes in serum creatinine included in modern definitions.

The optimal method for incorporating preadmission creatinine data into an accurate characterization of baseline

is complicated by methodologic challenges involving data availability, variability, and quality. In the absence of a consensus approach, we created a reference standard that matches typical clinical practice by having adjudicators review all available clinical data. Because implementing manual adjudication in large-scale observational studies of AKI is not feasible, we sought to identify a quantitative rule that could be applied to a cohort of hospitalized patients to accurately classify changes in kidney function during hospitalization. The superiority of the mean outpatient creatinine in matching the adjudicated value may reflect a clinical recognition by the adjudicators that averaging multiple serum creatinine values, if available, reduces the inappropriate effect of outliers or the known effect of physiologic variation (18–20). This latter observation suggests that for a large proportion of patients at risk for AKI, baseline kidney function may be more accurately described as a range than as a single value. Averaging of serial data

Table 3. Agreement between estimation method and adjudicated reference standard stratified by CKD status and number of preadmission serum creatinine values available

Estimation Method	ICC (95% CI)				
	eGFR < 60 ml/min per 1.73 m ² (n=259)	eGFR ≥ 60 ml/min per 1.73 m ² (n=120)	0–6 Creatinine Measurements (n=142)	6–14 Creatinine Measurements (n=111)	14–93 Creatinine Measurements (n=126)
Most recent outpatient	0.80 (0.74–0.85)	0.58 (0.42–0.70)	0.87 (0.80–0.91)	0.93 (0.89–0.95)	0.80 (0.71–0.86)
Mean outpatient	0.87 (0.83–0.90)	0.75 (0.65–0.83)	0.91 (0.87–0.94)	0.95 (0.93–0.97)	0.88 (0.83–0.91)
Nadir outpatient	0.76 (0.66–0.83)	0.65 (0.48–0.76)	0.89 (0.84–0.93)	0.93 (0.83–0.96)	0.76 (0.61–0.85)
Most recent inpatient or outpatient	0.85 (0.81–0.88)	0.65 (0.53–0.75)	0.89 (0.85–0.92)	0.92 (0.88–0.94)	0.86 (0.80–0.90)

CKD status was defined using the baseline adjudicated creatinine value. ICC, intraclass correlation coefficient; CI, confidence interval; eGFR, estimated GFR.

points during the recording of physiologic variables has already been found to enhance predictive power in other clinical settings. For example, both the American Heart Association and recent scientific literature have endorsed averaging multiple measurements in the recording of ambulatory BP for decision-making and quality reporting (21,22). This strategy is also commonly used to account for intraindividual variation in both establishing baseline and documenting changes in BP that occur in clinical trials of patients with hypertension (23).

Averaging of outpatient creatinine values may be less optimal in certain subsets of patients, especially if prevalent within a studied cohort. For example, the most recent serum creatinine may be most informative in patients with progressive CKD, especially among those with few data points (*e.g.*, two or fewer). Nonaveraged values in this subgroup of patients may also be useful in detailing the pre-morbid trajectory of kidney function. Because a large proportion of patients in our study population had pre-existing kidney impairment, this may partially explain why, despite lower ICCs, similar rates of potential AKI misclassification were observed between most recent serum creatinine values (Figure 1, A and D) and mean outpatient values. It may also partially explain why the nadir value, even when restricted to outpatient values, resulted in the largest proportion of patients potentially misclassified (Figure 1C).

Our data also suggest that the defined time interval for capturing baseline creatinine data affects accuracy. Creatinine measurements proximal to the admission date (*i.e.*, within a week) or remote (>1 year) often decrease accuracy. In patients in whom creatinine was recorded within a week of hospitalization, values tended to be higher than the adjudicated creatinine values (data not shown), suggesting that decreasing kidney function or increased creatinine turnover coincided with the onset of acute illness. Including more remote creatinine data (*e.g.*, >1 year) may improve sample size and reduce selection bias; however, this benefit must be weighed against the inability to account for interim changes in kidney function and ensure that decrements in kidney function observed on presentation are truly acute.

The study is limited by the data available within the electronic medical record of our institution; some preadmission

serum creatinine data measured elsewhere may be missing from the analysis. However, reviewers were allowed access to records scanned outside, and our requirement that patients have two preadmission serum creatinine measurements focused the analysis on patients typically followed within our institution. In addition, although not all adjudicators were trained at the same institution, the reference standard for baseline serum creatinine was determined within a single center, and we cannot rule out the contribution of potential institutional bias in the clinical interpretation of creatinine values. Finally, we enriched our population with patients who had abnormal kidney function during hospitalization, thereby increasing the possible effects of ascertainment bias. However, our sensitivity analysis demonstrating the consistently superior performance of mean averaged outpatient value across the spectrum of creatinine availability does not support this hypothesis. Nonetheless, these findings should be validated in other study settings.

In summary, using functional markers to define and study AKI and its consequences requires accurate quantification of baseline status. Use of averaged outpatient values between 7 and 365 days before admission yields a reliable rule for estimating baseline kidney function among high-risk patients in a tertiary care setting. Further work to validate this approach in other clinical settings, as well as to improve determination of baseline kidney function when preadmission data are not readily available, is warranted.

Acknowledgments

This work was funded by Grant R01 LM009965-01 from the National Library of Medicine. E.D.S. is supported by Grant K23 DK088964-01A1 from the National Institute of Diabetes and Digestive and Kidney Diseases. The work of M.E.M. is supported in full by the Career Development Program from the Department of Veterans Affairs (CDA-08-020 HSR&D). The work of A.M.H. is supported in full by the Career Development Program from the Department of Veterans Affairs (CDA [2-031-095] CSR&D).

Separate pilot data were presented in abstract form at the 2009 American Society of Nephrology Annual Scientific Meeting, October 27 to November 1, 2009, San Diego, California.

Disclosures

None.

References

- Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A: Acute Kidney Injury Network: Acute Kidney Injury Network: Report of an initiative to improve outcomes in acute kidney injury. *Crit Care* 11: R31, 2007
- Joannidis M, Metnitz B, Bauer P, Schusterschitz N, Moreno R, Druml W, Metnitz PG: Acute kidney injury in critically ill patients classified by AKIN versus RIFLE using the SAPS 3 database. *Intensive Care Med* 35: 1692–1702, 2009
- Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW: Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. *J Am Soc Nephrol* 16: 3365–3370, 2005
- Hsu CY, McCulloch CE, Fan D, Ordoñez JD, Chertow GM, Go AS: Community-based incidence of acute renal failure. *Kidney Int* 72: 208–212, 2007
- Nash K, Hafeez A, Hou S: Hospital-acquired renal insufficiency. *Am J Kidney Dis* 39: 930–936, 2002
- Bagshaw SM, George C, Bellomo R; ANZICS Database Management Committee: A comparison of the RIFLE and AKIN criteria for acute kidney injury in critically ill patients. *Nephrol Dial Transplant* 23: 1569–1574, 2008
- Hoste EA, Clermont G, Kersten A, Venkataraman R, Angus DC, De Bacquer D, Kellum JA: RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: A cohort analysis. *Crit Care* 10: R73, 2006
- Uchino S, Bellomo R, Goldsmith D, Bates S, Ronco C: An assessment of the RIFLE criteria for acute renal failure in hospitalized patients. *Crit Care Med* 34: 1913–1917, 2006
- Lopes JA, Fernandes P, Jorge S, Gonçalves S, Alvarez A, Costa e Silva Z, França C, Prata MM: Acute kidney injury in intensive care unit patients: A comparison between the RIFLE and the Acute Kidney Injury Network classifications. *Crit Care* 12: R110, 2008
- Siew ED, Matheny ME, Ikizler TA, Lewis JB, Miller RA, Waitman LR, Go AS, Parikh CR, Peterson JF: Commonly used surrogates for baseline renal function affect the classification and prognosis of acute kidney injury. *Kidney Int* 77: 536–542, 2010
- Fraser CG, Harris EK: Generation and application of data on biological variation in clinical chemistry. *Crit Rev Clin Lab Sci* 27: 409–437, 1989
- Delanaye P, Cavalier E, Krzesinski JM: Estimated glomerular filtration rate. *Ann Intern Med* 146: 74, 2007
- Donner A, Zou G: Testing the equality of dependent intraclass correlation coefficients. *Journal of the Royal Statistical Society Series D* 51: 367–379, 2002
- Liu KD, Lo L, Hsu CY: Some methodological issues in studying the long-term renal sequelae of acute kidney injury. *Curr Opin Nephrol Hypertens* 18: 241–245, 2009
- Bagshaw SM, Uchino S, Cruz D, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Oudemans-van Straaten HM, Ronco C, Kellum JA: A comparison of observed versus estimated baseline creatinine for determination of RIFLE class in patients with acute kidney injury. *Nephrol Dial Transplant* 24: 2739–2744, 2009
- Ricci Z, Cruz D, Ronco C: The RIFLE criteria and mortality in acute kidney injury: A systematic review. *Kidney Int* 73: 538–546, 2008
- Cruz DN, Bagshaw SM, Ronco C, Ricci Z: Acute kidney injury: Classification and staging. *Contrib Nephrol* 164: 24–32, 2010
- Bandaranayake N, Ankrah-Tetteh T, Wijeratne S, Swaminathan R: Intra-individual variation in creatinine and cystatin C. *Clin Chem Lab Med* 45: 1237–1239, 2007
- Toffaletti JG, McDonnell EH: Variation of serum creatinine, cystatin C, and creatinine clearance tests in persons with normal renal function. *Clin Chim Acta* 395: 115–119, 2008
- Coresh J, Astor BC, McQuillan G, Kusek J, Greene T, Van Lente F, Levey AS: Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. *Am J Kidney Dis* 39: 920–929, 2002
- Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ; Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research: Recommendations for blood pressure measurement in humans and experimental animals: Part 1: Blood pressure measurement in humans: A statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. *Hypertension* 45: 142–161, 2005
- Powers BJ, Olsen MK, Smith VA, Woolson RF, Bosworth HB, Oddone EZ: Measuring blood pressure for decision making and quality reporting: Where and how many measures? *Ann Intern Med* 154: 781–788, W-289–W-290, 2011
- ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA* 288: 2981–2997, 2002

Received: October 19, 2011 **Accepted:** February 16, 2012Published online ahead of print. Publication date available at www.cjasn.org.

See related editorial, “Predicting Baseline Creatinine in Hospitalized Patients,” on pages 697–699.

Access to UpToDate on-line is available for additional clinical information at www.cjasn.org.

Appendix

Diagnosis	Definition
Hypertension	ICD-9 Outpatient or Inpatient Discharge Codes: 401*, 402*, 403*, 404*, and 405*
Diabetes Mellitus	ICD-9 Outpatient or Inpatient Discharge Codes: 250* (primary diabetes), 249* (secondary diabetes), 357.2* (neuropathy in diabetes), 362* (diabetic retinopathy), 366.41* (diabetic cataract), 648* (diabetes in pregnancy)
Coronary Artery Disease	ICD-9 Outpatient or Inpatient Discharge Codes: 440*, 410*, 411*, 413*, 414*
Peripheral Vascular Disease	ICD-9 Outpatient or Inpatient Discharge Codes: 443*, 440.2*, 440.3*, 440.4*
Dialysis	Inpatient ICD-9 Procedure Codes: 12.55, 39.95*, 54.98* Outpatient and Fee Basis ICD-9 Diagnosis Codes: 585.6, V45.1, V56.0, V56.2, V56.3, V56.31, V56.32, V56.8, V58.8 Outpatient CPT Codes: 90935, 90937, 90947, 90989, 90993, 90921, 90925
Congestive Heart Failure	ICD-9 Outpatient or Inpatient Discharge Codes: 428*, 425*, 398.91, 402.01, 402.11, 402.91, 404.91, 404.93
Hospice	ICD-9 Outpatient or Inpatient Discharge Codes: V66.7* Outpatient CPT Codes: 99377
Renal transplant	ICD-9 Outpatient or Inpatient Discharge Codes: 55.6, 55.61, 55.69, 996.81, V42.0 ICD-9 Inpatient Procedure Codes: 00.91, 00.92, 00.93 Outpatient CPT Codes: 50380, 50365, 50360